Advanced Search:

XBIO - Xenetic Biosciences

$1.15  -0.02 (-1.71%)

Updated: 04:18 Jan 20, 2022 EST

$1.20  0.05 (4.35%)

Premarket (Updated At 2022-01-20 09:18:25)

Accuracy AVG (AI)

66.29%

Next Week
Trend's Accuracy (AI)

100%

Equity Rank Position

Overall Rank Position

Innrs Rank

Now

23.89

This Week

23.7

This Qtr.

23.33

Next Qtr.

28.07

This Year

33.75

Buy Strength

Xenetic Biosciences's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

XENETIC BIOSCIENCES - HISTORICAL DATA 6M

  • Last price

    $ 1.15

  • Daily change

    $ -0.02

  • Previous Close

    $ 1.17

  • Last Updated

    04:18 Jan 20, 2022 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
-3.4 -0.85 -0.74 -0.77 -0.6

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
3.4 3.37 3.37 4.6 4.55

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
0% 0% 0% 0%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
1.27 -5.22% 1.34 -2.19% 1.37 -30.46% 1.97

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
N/A N/A N/A N/A

Xenetic Biosciences

40 Speen Street
Suite 102
Framingham, MA 01701
United States
781-778-7720
http://www.xeneticbio.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 4
Description

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and novel oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Corporate Governance

Xenetic Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

XENETIC BIOSCIENCES'S HOLDERS RANK

List of holders with stock participation in Xenetic Biosciences.